Kaliumchlorid/Glucose B. Braun

Potassium chloride, the active ingredient in Kaliumchlorid/Glucose B. Braun, is an electrolyte and carbohydrate solution presented as an injectable solution for intravenous use. It is employed to correct low potassium levels and to provide glucose for energy, often in patients receiving intravenous therapy. GNH USA supplies Kaliumchlorid/Glucose B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kaliumchlorid/Glucose B. Braun is used in clinical situations that require electrolyte and carbohydrate support. - Hypokalemia: restores serum potassium concentrations in patients with potassium deficiency. - Potassium replacement therapy: provides controlled potassium supplementation during acute care. - Fluid and electrolyte replenishment: contributes to overall electrolyte balance in intravenous fluid regimens. - Prevention of hypoglycemia during intravenous therapy: supplies glucose to maintain blood sugar levels while delivering potassium.

Adverse reactions may occur with any intravenous electrolyte solution.

Common Side Effects: - Injection site irritation or pain - Transient hyperglycemia - Mild nausea or vomiting - Headache or dizziness - Temporary hyperkalemia if administered rapidly - Mild electrolyte imbalance symptoms

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia - Anaphylactic or severe allergic reaction - Life‑threatening cardiac arrest - Severe hypoglycemia - Metabolic acidosis - Hemolysis or severe vein irritation

Careful assessment and monitoring are required when using this intravenous solution. - Serum potassium assessment: verify baseline potassium levels before infusion. - Cardiac monitoring: observe ECG for arrhythmias during and after administration. - Renal impairment: adjust dose or infusion rate in patients with reduced kidney function. - Infusion rate: avoid rapid administration exceeding recommended limits. - Diabetes caution: monitor blood glucose closely in diabetic patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may increase serum potassium to dangerous levels. - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia. - NSAIDs: can reduce renal potassium excretion, heightening hyperkalemia risk.

Moderate Interactions (Monitor Closely): - Insulin therapy: glucose component may potentiate insulin‑induced hypoglycemia; monitor glucose. - Beta‑blockers: may mask symptoms of hypoglycemia and affect potassium handling.